Study to determine the safety tolerability pharmacokinetics and pharmacodynamics of DNL201 in subjects with Parkinsons Disease
Enrolling By Invitation
18 years - 99 years
All
Phase
1
6 participants needed
1 Location
Brief description of study
The purpose of this research is to investigate whether DNL201 (the study drug) is safe
and tolerable in Parkinson’s disease patients and to investigate how DNL201 is absorbed, broken
down, and eliminated from the body.
Detailed description of study
Duration: It is expected that your participation will last approximately 10 weeks, including the Follow-Up Period. The Treatment Period for this study is approximately 28 days.
Procedures and Activities: During this study, you will be required to visit the study site at least 8 times, not including the Screening Period. Two of these visits include inpatient stays (overnight) for 5 days and 4 nights. For the first inpatient stay, you will be admitted to the Center for Human Phenomic Science (CHPS) starting 2 days prior to the date of the first dose of study drug (the Baseline Period) through Day 3 of the Treatment Period. The second inpatient stay will start near the end of the Treatment Period during which you will be admitted to the inpatient unit starting on Day 26 through Day 30.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: PARKINSONS DISEASE
-
Age: 18 years - 99 years
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 832409
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
